Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer
Randomized Phase II Study for Dose Escalation in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated With Radiochemotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Daniel Zips, Prof. Dr. med.
- Phone Number: +49 7071 29 82141
- Email: daniel.zips@med.uni-tuebingen.de
Study Contact Backup
- Name: Silke Theden, Mrs.
- Phone Number: +49 7071 29 83420
- Email: silke.theden@med-uni-tuebingen.de
Study Locations
-
-
Baden-Württemberg
-
Tuebingen, Baden-Württemberg, Germany, 72076
- Recruiting
- Tuebingen university, radiation oncology
-
Contact:
- Stefan Welz, Dr. med.
- Phone Number: +49 7071 29 86144
- Email: stefan.welz@med.uni-tuebigen.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- histologically verified squamous cell carcinoma of the head and neck region stage III and IV eligible for primary radiochemotherapy
- measurabel disease by CT and/or MRT and/or FDG-PET-CT
- fit for chemotherapy
- no prior radiotherapy or major surgery in the head/neck region
- Karnofsky Index > 60%
- informed consent
Exclusion Criteria:
- uncontrolled secondary cancer
- distant metastases
- pregnancy
- expected malcompliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard therapy
Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
|
|
|
Experimental: dose escalation
Standard plus 10% dose escalation to the hypoxic volume
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
time to local recurrence
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stefan Welz, Dr. med., Radiation Oncology
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2.0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.